ARTICLE | Regulation
Obesity Obstacles
Modest efficacy, uncertain risk: FDA panel pans Arena's lorcaserin for obesityObesity drugs may dwindle: FDA told Abbott's Meridia poses too much cardio risk
September 20, 2010 7:00 AM UTC
The outcomes of three recent FDA advisory committee meetings provide clues for companies still interested in developing candidates for obesity.
Last week, FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 that the benefit-risk profile of lorcaserin from Arena Pharmaceuticals Inc. does not support approval to treat obesity...